Trial Profile
A retrospective study of ceftolozane/tazobactam in patients with multidrug-resistant Pseudomonas aeruginosa infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2016
Price :
$35
*
At a glance
- Drugs Ceftolozane/tazobactam (Primary)
- Indications Gram-negative infections
- Focus Therapeutic Use
- 19 Dec 2016 New trial record
- 12 Dec 2016 Results published in the Antimicrobial Agents and Chemotherapy.